SCHEMBL2533931

SCHEMBL2533931

O=Cc1ccc2c(c1)oc1ccccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.54
MEN1 O00255 5/20 0.54
KMT2A Q03164 5/20 0.54
AHR P35869 2/20 0.53
KDM4E B2RXH2 5/20 0.52
ALDH1A1 P00352 4/20 0.52
HPGD P15428 4/20 0.52
KIF11 P52732 2/20 0.49
MAOA P21397 4/20 0.47
SMN1; SMN2 Q16637 5/20 0.47
GLA P06280 1/20 0.47
CYP3A4 P08684 1/20 0.47
PGAM1 P18669 1/20 0.47
CASP1 P29466 1/20 0.47
CASP7 P55210 1/20 0.47
HSD17B10 Q99714 1/20 0.47
NPC1 O15118 5/20 0.44
RAB9A P51151 5/20 0.44
CYP1A2 P05177 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1784418 0.91 MAOA (0.62) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL6856438 0.90 CYP2A6 (0.45) MAPTMEN1KMT2AAHRKDM4E
SCHEMBL30367521 0.90 CYP2A6 (0.45) MAPTMEN1KMT2AAHRKDM4E
SCHEMBL1420897 0.89 MAPT (0.53) MAPTMEN1KMT2AAHRKDM4E
SCHEMBL3566155 0.81 AHR (0.53) MAPTMEN1KMT2AAHRKDM4E
SCHEMBL26769530 0.81 AHR (0.53) MAPTMEN1KMT2AAHRKDM4E
SCHEMBL1784133 0.80 MAOA (0.62) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL11764173 0.80 TDP1 (0.47) MAPTMEN1KMT2AAHRKDM4E
SCHEMBL19152346 0.79 MAPT (0.58) MAPTMEN1KMT2AAHRKDM4E
SCHEMBL13242796 0.79 ALDH1A1 (0.47) MAPTMEN1KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030018016-A1 Cell adhesion inhibitors BIOGEN IDEC MA, INC. 2003-01-23 US claimed
EP-0805796-B1 CELL ADHESION INHIBITORS BIOGEN INC (US) 2002-12-11 EP claimed
US-6376538-B1 ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES BIOGEN, INC. 2002-04-23 US claimed
CN-1177343-A Cell adhesion inhibitors BIOGEN INC (US) 1998-03-25 CN claimed
EP-0805796-A1 CELL ADHESION INHIBITORS BIOGEN, INC. (US) 1997-11-12 EP claimed
WO-1996022966-A1 CELL ADHESION INHIBITORS BIOGEN, INC. (US) 1996-08-01 WO claimed
JP-61171478-A None JP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
US-11917901-B2 Metal complexes UDC IRELAND LIMITED (IE) 2024-02-27 US disclosed
US-11917901-B2 Metal complexes UDC IRELAND LIMITED (IE) 2024-02-27 US disclosed
US-11005050-B2 Metal complexes MERCK PATENT GMBH (DE) 2021-05-11 US disclosed
EP-3424936-B1 METAL COMPLEXES MERCK PATENT GMBH (DE) 2021-04-07 EP disclosed
CN-105377863-B polycyclic compounds 默克专利有限公司 2019-03-01 CN disclosed
CN-1177343-A Cell adhesion inhibitors BIOGEN INC (US) 1998-03-25 CN disclosed
EP-0805796-A1 CELL ADHESION INHIBITORS BIOGEN, INC. (US) 1997-11-12 EP disclosed
WO-1996022966-A1 CELL ADHESION INHIBITORS BIOGEN, INC. (US) 1996-08-01 WO disclosed
JP-S61171478-A PRODUCTION OF 2-HYDROXYDIPHENYLENE OXIDE NIPPON STEEL CORP 1986-08-02 JP disclosed
US-4217301-A Cyano-substituted stilbene compounds CIBA-GEIGY CORPORATION (US) 1980-08-12 US disclosed
US-4097515-A Process for the manufacture of cyano-substituted stilbene compounds CIBA-GEIGY CORPORATION (US) 1978-06-27 US disclosed
US-4008224-A OPTICAL BRIGHTENER CIBA-GEIGY CORPORATION (US) 1977-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11005050-B2 Metal complexes SOD1, AP1M1, AP3M1 MAPT 1084/4885MEN1 989/4885KMT2A 2922/4885
US-20030018016-A1 Cell adhesion inhibitors ICAM1, VCAM1, EPCAM MAPT 2771/4885MEN1 1437/4885KMT2A 3376/4885
US-11917901-B2 Metal complexes MCOLN2, MCOLN1, AP1M1 MAPT 2472/4885MEN1 63/4885KMT2A 1876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.